A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Ozempic, which accounts for 41% of the company's sales, is an injectable anti-diabetic treatment that became wildly popular ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

An observational analysis finds the drugs may lower the risk of substance abuse and cognitive issues. But the findings need ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...